Volodimir Olexiouk, our Director of Scientific Engagement and Data Science Team Lead, was featured on episode 205 of Cynozure‘s Hub & Spoken podcast.
In this episode, Cynozure CEO and podcast host Jason Foster speaks with Volodimir about the revolutionary intersection of artificial intelligence and pharmaceuticals, exploring how AI is transforming the landscape of drug discovery.
Tune in now and gain insights into the innovative ways AI is transforming drug discovery and shaping the future of healthcare and biotechnology.
Want to learn more about how leveraging artificial intelligence can support your research & development activities? Check out our white paper about how you can use machine learning to develop better biomarkers – a powerful tool for de-risking drug discovery projects.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
